公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2012 | Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma | Yen C.-H.; Lu Y.-C.; Li C.-H.; Lee C.-M.; Chen C.-Y.; Cheng M.-Y.; Huang S.-F.; Chen K.-F.; ANN-LII CHENG ; Liao L.-Y.; Lee Y.-H.W.; Chen Y.-M.A. | Molecular Medicine | 52 | 48 | |
2010 | Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells | DA-LIANG OU ; Ying-Chun Shen ; SUNG-LIANG YU ; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; LIANG-IN LIN ; CHIUN HSU ; ANN-LII CHENG | Cancer Research | 70 | 69 | |
2012 | Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells | Chen K.-F.; Lin J.-P.; Shiau C.-W.; Tai W.-T.; Liu C.-Y.; Yu H.-C.; PEI-JER CHEN ; ANN-LII CHENG | Biochemical Pharmacology | 50 | 50 | |
2013 | Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma | Yu H.-C.; Chen H.-J.; Chang Y.-L.; Liu C.-Y.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F. | Biochemical Pharmacology | 45 | 44 | |
2013 | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells | Tai W.-T.; Shiau C.-W.; Chen H.-L.; Liu C.-Y.; Lin C.-S.; ANN-LII CHENG ; PEI-JER CHEN ; Chen K.-F. | Cell Death and Disease | 159 | 159 | |
2019 | Measurement of rare B → ?? decays and search for τ → 3? decays at CMS | Chen K.-F.; KAI-FENG CHEN | Proceedings of Science | 0 | ||
2008 | OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma | Gao M.; Yeh P.Y.; YEN-SHEN LU ; CHIH-HUNG HSU ; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG | Cancer Research | 131 | 123 | |
2018 | Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response | CHAO YUAN HUANG ; Hsieh F.-S.; Wang C.-Y.; Chen L.-J.; Chang S.-S.; Tsai M.-H.; Hung M.-H.; Kuo C.-W.; Shih C.-T.; Chao T.-I.; Chen K.-F. | European Journal of Cancer | 49 | ||
2019 | Rare decays at CMS | Chen K.-F.; KAI-FENG CHEN | Proceedings of Science | 0 | ||
2013 | SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells | CHEN-TI WANG ; Lin C.-S.; Shiau C.-W.; Chu P.-Y.; Hsiao C.-C.; Chiang Y.-L.; Tai W.-T.; Chen K.-F. | Journal of Orthopaedic Research | 9 | 6 | |
2014 | SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model | Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN ; Chen K.-F. | Molecular Cancer Therapeutics | 7 | 6 | |
2018 | Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma | Hu M.-H.; Huang T.-T.; Chao T.-I.; Chen L.-J.; Chen Y.-L.; Tsai M.-H.; Liu C.-Y.; JIA-HORNG KAO ; Chen K.-F. | Liver International | 7 | 6 | |
2014 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer | Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN ; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Journal of Thoracic Oncology | 11 | 11 | |
2011 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; HSIANG-PO HUANG ; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 146 | 140 | |
2015 | Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver Through SHP-1 | Wang S.-H.; Shiou-Hwei Yeh ; Shiau C.-W.; Chen K.-F.; Lin W.-H.; Tsai T.-F.; Teng Y.-C.; DING-SHINN CHEN ; PEI-JER CHEN | Journal of the National Cancer Institute | 20 | 14 | |
2013 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody | Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN ; ANN-LII CHENG | British Journal of Pharmacology | 16 | 13 | |
2011 | Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf | Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG ; PEI-JER CHEN ; Shiau C.-W. | European Journal of Medicinal Chemistry | 32 | 29 | |
2010 | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3 | Chen K.-F.; Tai W.-T.; TSUNG-HAO LIU ; HSIANG-PO HUANG ; Lin Y.-C.; Shiau C.-W.; Li P.-K.; PEI-JER CHEN ; ANN-LII CHENG | Clinical Cancer Research | 147 | 145 | |
2014 | STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma | Tai W.-T.; Chu P.-Y.; Shiau C.-W.; Chen Y.-L.; Li Y.-S.; Hung M.-H.; Chen L.-J.; PEI-LUNG CHEN ; Su J.-C.; Lin P.-Y.; Yu H.-C.; Chen K.-F. | Clinical Cancer Research | 79 | 72 | |
2010 | Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation | Chen K.-F.; Yu H.-C.; TSUNG-HAO LIU ; SHOEI-SHENG LEE ; PEI-JER CHEN ; ANN-LII CHENG | Journal of Hepatology | 68 | 67 |